SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing recurrent respiratory papillomatosis treatment has raised concerns about competition for Precigens PAPZIMEOS. Traders debate the threat to sales, with some emphasizing Precigens full-approval and commercial head start while others argue the rivals treatment could offer patients a meaningful alternative; Inovios accelerated-approval status and commercialization challenges are also points of discussion.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons third-quarter earnings beat, supported by strong refining profits and record U.S. refinery throughput, is driving attention. Traders are reacting positively to the results and cash generation, while some question whether elevated refining margins are sustainable and point to the stocks recent run-up.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASMLs quarterly results, raised sales outlook and warning that planned equipment supply will fall short of customer demand are driving discussion. Despite strong AI-related demand, traders are debating why the shares fell after the report, citing high expectations and the lack of a next-year outlook, while others view the decline as a sell-the-news reaction.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON is drawing attention amid a pullback in analog and auto-focused semiconductor stocks, with traders also noting broader market weakness and no clear company-specific headline behind the decline. Reactions are mixed: some view the drop as a buying opportunity, while others expect further downside; options activity is split between calls and puts.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention: shares rose despite revenue and EPS misses, as traders focused on subscriber growth and improving gross margin. The reaction is divided, with bulls emphasizing the upbeat guidance and bears pointing to higher expenses and the earnings shortfall.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradynes quarterly results beat expectations, but traders are focused on the softer near-term outlook, expected margin pressure and growth weighted toward the second half of next year as the stock sells off. Some view the pullback as a buying opportunity, while others point to bearish options activity and weakening technical support.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.42916419 USD and is up 8.20 over the last 24 hours. It is currently trading on 2313 active market(s) with $611,471,639.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rally and rising volume have drawn attention, with traders pointing to Chainlinks CCIP 2.0 announcement and institutional tokenization integrationsincluding Coinbases selection of Chainlink infrastructureas bullish context. Some expect the momentum to continue, while skeptics question whether network adoption translates into value for LINK and warn the move could fade;

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00385003 USD and is up 3.25 over the last 24 hours. It is currently trading on 374 active market(s) with $20,884,591.23 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMYs volatile price action is driving debate, with bulls pointing to the AppBank AI/data-services collaboration and JasmyChain utility as signs of progress, while skeptics question whether these developments will translate into real adoption and demand. Dip-buying posts contrast with concerns about weak performance, exchange delisting chatter, and broader crypto-market weakness.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLAs quarterly results beat estimates and its next-quarter outlook was strong, but shares have sold off as traders debate whether the results cleared elevated expectations amid broader semiconductor-equipment weakness. Some view the pullback as an opportunity, while others point to valuation and analyst price-target cuts as reasons for caution.

BankrCoin (BNKR) is a cryptocurrency and operates on the Base platform. BankrCoin has a current supply of 100,000,000,000 with 99,389,999,999.99966667 in circulation. The last known price of BankrCoin is 0.00029512 USD and is up 9.48 over the last 24 hours. It is currently trading on 84 active market(s) with $2,292,823.67 traded over the last 24 hours. More information can be found at https://warpcast.com/bankr.

BankrCoin

Bankrs AI-agent trading infrastructure, expanding ecosystem integrations, and fee-linked buybacks and staking dominate the discussion, with traders arguing that growing usage and revenue could support BNKRs value. Others are focused on volatile price action and whether the activity will translate into sustained gains, while many breakout calls remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veru (VERU) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Equity

Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Others

Veru (VERU) Q1 2026 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

A Look Ahead: Veru's Earnings Forecast

Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm 

VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.

Veru Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Veru stated in a regulatory filing that it will sponsor and conduct the Phase 2b PLATEAU study, while Novo Nordisk will provide Wegovy at no cost for use in the trial.</li><li>It will also share study-related updates with Novo Nordisk, including information on trial design, protocol amendments, and safety data.</li><li>The company said it will retain full global development and commercialization rights to enobosarm.</li></ul><p>Shares of Veru Inc. (VERU) soared more than 160% in Thursday morning’s trade after the company announced that it had entered into a clinical supply agreement with Novo Nordisk AS (NVO).</p><p>Under the agreement, Veru will evaluate enobosarm alongside Novo Nordisk's Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.</p><p><a href="https://stocktwits.com/symbol/VERU">Veru shares</a> were up more than 158% during Thursday morning’s trade after paring some of the gains.</p><h2 class="st-heading-2">VERU Retains Global Rights To Enobosarm</h2><p>Veru stated in a filing with the U.S. Securities and Exchange Commission (SEC) that it will sponsor and conduct the Phase 2b PLATEAU study, while Novo Nordisk will provide Wegovy at no cost for use in the trial.</p><p>Veru will also share study-related updates with Novo Nordisk, including information on trial design, protocol amendments, and safety data. The company said it will retain full global development and commercialization rights to enobosarm.</p><p>Veru also granted Novo Nordisk a right of first negotiation for any future agreement involving enobosarm in combination with Novo Nordisk GLP-1 therapies, including Wegovy.</p><h2 class="st-heading-2">Canaccord Sees NVO Deal As Major Validation</h2><p>According to TheFly, Canaccord described the Novo Nordisk agreement as a significant milestone for Veru, saying it validates interest in enobosarm from one of the leading players in the obesity market.</p><p>The firm added that it continues to view Veru's clinical data as compelling and believes enobosarm could emerge as a key differentiator in obesity treatment.</p><p>Canaccord reiterated its ‘Buy’ rating and $25 price target on the stock.</p><h2 class="st-heading-2">What Is VERU's Phase 2b PLATEAU Study About?</h2><p>The Phase 2b PLATEAU trial is evaluating Veru's enobosarm in approximately 200 adults aged 65 and older with obesity who are beginning treatment with Wegovy.</p><p>The study aims to determine whether enobosarm can preserve muscle mass and physical function, helping patients overcome the weight-loss plateau often seen with GLP-1 therapies.</p><p>Veru expects interim data on lean mass and fat mass in the first quarter of 2027, with topline results anticipated in the fourth quarter of 2027.</p><h2 class="st-heading-2">How Did Retail Traders React To VERU Stock?</h2><p>Retail sentiment on Stocktwits around Veru trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.</p><p><a href="https://stocktwits.com/symbol/VERU">VERU stock</a> is up 154% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/VERU">NVO stock</a> is down 14%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 29%.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spacex-ai-revenue-soar-100-times-322b-2030-spcx-ipo-roadshow/cZ0ZKosReyw"><strong>SpaceX's AI Revenue Could Eclipse Starlink — Goldman Forecasts 100-Fold Surge To $322 Billion By 2030</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shares of REalloys Inc. surged on Monday (Representative image: Getty Images)

Shares of Veru Inc. (VERU) soared more than 160% in Thursday morning’s trade after the company announced that it had entered into a clinical supply agreement with Novo Nordisk AS (NVO).

Novo Nordisk A/S

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.19
Prev Close	$2.23
Open	$2.25
Dividend Yield	0.00%
50-Day Moving Average	$2.46
Beta	1.70
Avg. Volume	201,022.89
PE Ratio	-3.58

52-Week High	$7.33
52-Week Low	$2.05
Market Capitalization	$37.34M
EPS (Annual)	-$1.27
Price to Book	1.32
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERU Fundamentals